EP
ALXN

Eudaimonia Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Eudaimonia Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-63
Closed -$10K – 1517
2021
Q1 		$10K Sell
63
-200
-76% -$30.9K ﹤0.01% 1178
2020
Q4 		$41K Sell
263
-25
-9% -$3.21K 0.01% 660
2020
Q3 		$33K Buy
288
+78
+37% +$8.41K 0.01% 663
2020
Q2 		$24K Buy
+210
New +$22.3K 0.01% 687

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Eudaimonia Partners's ALXN Position: Q2 2021 in Review

Eudaimonia Partners sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 63 shares — an estimated $10K sold.

Eudaimonia Partners first reported a position in ALXN in Q2 2020 and held it in 4 quarters. The position peaked at $41K in Q4 2020. 710 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Eudaimonia Partners reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Eudaimonia Partners sold 63 Alexion Pharmaceuticals shares in Q2 2021, an estimated $10K.
  • Eudaimonia Partners first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 4 quarters.
  • Eudaimonia Partners's Alexion Pharmaceuticals position peaked at $41K in Q4 2020.
  • 710 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Eudaimonia Partners's 13F filing for Q2 2021, filed 13 Aug 2021.